Immunomodulators, agents that can stimulate or suppress the immune system, are being studied for their role in managing HIV. These drugs target immune mediators such as lymphocytes, macrophages, and neutrophils to regulate immune responses. As of 2026, research focuses on their potential to reduce inflammation and improve immune function in people living with HIV.
Current evidence suggests that immunomodulators may help control HIV-related immune activation, which is linked to disease progression. However, their use is not standard in clinical practice due to limited large-scale trials. A 2024 review in Infectious Disease Special Edition highlighted the need for more studies to establish safety and efficacy.
Experts emphasize that antiretroviral therapy (ART) remains the cornerstone of HIV treatment. Immunomodulators are considered adjunctive therapies, potentially beneficial for patients with persistent immune dysfunction despite viral suppression. Ongoing trials are exploring agents like interleukin-2 and interferon-gamma.
In summary, while immunomodulators offer theoretical benefits, their clinical application in HIV is still experimental. Patients should consult healthcare providers before considering such treatments.
